Information service “Clinical Research Database” in the rational prescription of antiplatelet agents
https://doi.org/10.37489/2588-0519-GCP-0002
EDN: DIPQVF
Abstract
Relevance. The relevance of primary and secondary prevention of cardiovascular disasters associated with atherothrombotic complications has increased in recent decades and is due to the steady increase in diseases of the circulatory system. In this regard, both long-known medicinal products with antiplatelet properties and innovative products are of particular interest.
Objective. Conduct an information search and fill the “Clinical Research Database” service for antiplatelet agents with high levels of proven efficacy and manageable safety.
Materials and methods. Search and analysis of the results of randomized clinical trials and meta-analysis were conducted in the international databases of medical publications with subsequent submission of the results to the “Clinical Research Database” for antiplatelet agents.
Results. Antiplatelet agents have a positive effect on “hard” endpoints of randomized clinical trials in the form of a statistically significant decrease in the number of cardiovascular complications and mortality.
Conclusions. The information service “Clinical Research Database” and evidence-based information about antiplatelet agents can be used by healthcare professionals for the rational prescription of medicines in clinical practice.
About the Authors
E. V. Eliseeva
Pacific State Medical University
Russian Federation
Competing Interests:
Russian Federation
Ekaterina V. Eliseeva — Dr. Sci. (Med.), Professor, Head of Department of General and Clinical Pharmacology
Vladivostok
Competing Interests:
The authors declare that there is no potential conflict of interest related to this work.
E. S. Maneeva
Pacific State Medical University
Russian Federation
Competing Interests:
Russian Federation
Elena S. Maneeva — Dr. Sci (Med.), Associated Professor of Department of General and Clinical Pharmacology
Vladivostok
Competing Interests:
The authors declare that there is no potential conflict of interest related to this work.
A. V. Tyrtyshnikova
Pacific State Medical University
Russian Federation
Competing Interests:
Russian Federation
Anna V. Tyrtyshnikova — PhD, Cand. Sci. (Med), Associated Professor of Department of General and Clinical Pharmacology
Vladivostok
Competing Interests:
The authors declare that there is no potential conflict of interest related to this work.
O. N. Li
Pacific State Medical University
Russian Federation
Competing Interests:
Russian Federation
Olga N. Li — Dr. Sci. (Med.), Professor of Department of General and Clinical Pharmacology
Vladivostok
Competing Interests:
The authors declare that there is no potential conflict of interest related to this work.
V. V. Gribova
Institute of Automation and Control Processes Far Eastern Branch of Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
Valeriya V. Gribova — Dr. Sc. (Tech.), Research Deputy Director
Vladivostok
Competing Interests:
The authors declare that there is no potential conflict of interest related to this work.
D. B. Okun
Institute of Automation and Control Processes Far Eastern Branch of Russian Academy of Sciences
Russian Federation
Competing Interests:
Russian Federation
Dmitry B. Okun — PhD, Cand. Sci. (Med), Scientific Employee, Laboratory Intelligent Systems
Vladivostok
Competing Interests:
The authors declare that there is no potential conflict of interest related to this work.
References
1. Antithrombotic Therapy in Scales and Algorithms: Clinical Guidelines for Physicians: Third Joint Clinical Guidelines of the National Scientific Society of Inflammation and the Russian Scientific Medical Society of Internal Medicine. Lomakin NV, et al. Moscow, 2020. (In Russ.). ISBN 978-5-6042468-9-4.
2. Laguta PS, Karpov YuA. Aspirin: History and Modernity. RMJ. 2012;(25):1256. (In Russ.).
3. Yakovishin LA. Acetylsalicylic Acid: History of obtaining and current use. Scientific Notes of the VI Vernadsky Crimean Federal University. Biology. Chemistry. 2022;8(74),4:304-323. (In Russ.).
4. Preferanskaya NG. Antiplatelet Agents (Part 1). Moscow Pharmacies: Pharmaceutical Newspaper. 17.07.2017 [Internet]. (In Russ.). Доступно по: https://mosapteki.ru/material/antiagregantnye-sredstva-ch-1-8766/ Ссылка активна на 28.08.2025.
5. Preferanskaya NG. Antiplatelet Agents (Part 2). Moscow Pharmacies: Pharmaceutical Newspaper. 11.08.2017 [Internet]. (In Russ.). Доступно по: https://mosapteki.ru/material/antiagregantnye-sredstva-ch-2-8894/ Ссылка активна на 28.08.2025.
6. Instructions for the medical use of Acetylsalicylic acid (tablets) [Electronic resource]. (In Russ.). Доступно по: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=4e403334-6abe-4fdc-af28-5d717700557c/ Ссылка активна на 28.08.2025.
7. Instructions for the medical use of Clopidogrel (tablets) [Electronic resource]. (In Russ.). Доступно по: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=c55f9d89-45de-4a13-9cdb-83a2d5a2e355/ Ссылка активна на 28.08.2025.
8. Instructions for the medical use of Ticagrelor (tablets) [Electronic resource]. (In Russ.) Доступно по: https://grls.minzdrav.gov.ru/Grls_View_v2.aspx?routingGuid=01172f32-3296-4a87-b4f7-44e996d1be3d/ Ссылка активна на 28.08.2025.
9. Stable coronary artery disease: clinical guidelines. Developer of clinical guidelines: Russian Society of Cardiology. Approved by the Ministry of Health of the Russian Federation. Year of approval: 2024. (In Russ.). Доступно по: https://cr.minzdrav.gov.ru/preview-cr/155_2/ Ссылка активна на 28.08.2025.
10. Acute myocardial infarction with ST-segment elevation on the electrocardiogram: clinical guidelines. Developer of clinical guidelines: Russian Society of Cardiology. Approved by the Ministry of Health of the Russian Federation. Year of approval: 2024. (In Russ.). Доступно по: https://cr.minzdrav.gov.ru/preview-cr/157_5/ Ссылка активна на 28.08.2025.
11. iacpaas.dvo.ru/ [интернет]. Облачная платформа для разработки, управления и удаленного использования интеллектуальных облачных сервисов: IACPaaS. Доступ по: https://iacpaas.dvo.ru/ Ссылка активна на 28.08.2025.
12. National Library of Medicine (PubMed) [Internet]. - [cited 2025 August 28]. Available from: https://pubmed.ncbi.nlm.nih.gov
13. Elsevier [Internet] - [cited 2025 August 28]. Available from: https://www.elsevier.com
14. Cochrane [Internet]. - [cited 2025 August 28]. Available from: https://www.cochrane.org
15. State Register of Medicines: official publication of the Ministry of Health of the Russian Federation. (In Russ.). Доступно по: https://grls.rosminzdrav.ru/ Ссылка активна на 28.08.2025.
16. Rubricator of Clinical Recommendations of the Ministry of Health of the Russian Federation. (In Russ.). Доступно по: https://cr.minzdrav.gov.ru/ Ссылка активна на 28.08.2025.
17. Drapkina OM, Vavilova TV, Karpov YuA, et al. The resolution of the Expert Council on current issues of the use of acetylsalicylic acid for the purpose of primary prevention of cardiovascular diseases in the light of new scientific data and updated clinical guidelines. Cardiovascular Therapy and Prevention. 2022;21(12):3487. (In Russ.). doi: 10.15829/1728-8800-2022-3487. EDN: JXEBFN.
18. Gelbenegger G, Postula M, Pecen L, et al. Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups. BMC Medicine. 2019;17(1):198. doi: 10.1186/s12916-019-1428-0.
19. Seidu S, Kunutsor SK, Sesso HD, et al. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. Cardiovascular Diabetology. 2019;18(1):70. doi: 10.1186/s12933-019-0875-4.
20. Abdelaziz HK, Saad M, Pothineni NVK, et al. Aspirin for Primary Prevention of Cardiovascular Events. J Am Coll Cardiol. 2019 Jun 18;73(23):2915-2929. doi: 10.1016/j.jacc.2019.03.501.
21. Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet. 2021;398(10306):1133-46. doi: 10.1016/S0140-6736(21)01827-4.
22. Creager MA. Results of the CAPRIE trial: efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. Vasc Med. 1998;3(3):257-60. doi: 10.1177/1358836X9800300314.
23. Mehta SR, Yusuf S; Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J. 2000 Dec;21(24):2033- 41. doi: 10.1053/euhj.2000.2474.
24. Sabatine MS, Cannon CP, Gibson CM, et al; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005 Mar 24;352(12):1179-89. doi: 10.1056/NEJMoa050522.
25. Chen ZM, Jiang LX, Chen YP, et al; COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005 Nov 5;366(9497):1607-21. doi: 10.1016/S0140-6736(05)67660-X.
26. Wang Y, Pan Y, Zhao X, et al; CHANCE Investigators. Clopidogrel With Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE) Trial: One-Year Outcomes. Circulation. 2015 Jul 7;132(1):40-6. doi: 10.1161/CIRCULATIONAHA.114.014791.
27. Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, Kim AS, Lindblad AS, Palesch YY; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med. 2018 Jul 19;379(3):215-225. doi: 10.1056/NEJMoa1800410.
28. Garg N, Kumar A, Flaker GC. Antiplatelet therapy for stroke prevention in atrial fibrillation. Mo Med. 2010 Jan-Feb;107(1):44-7.
29. Steinhubl SR, Berger PB, Mann JTIII, et al. CREDO Investigators. Clopidogrel for the reduction of events during observation. JAMA. 2002; 288(19):2411-2420.
30. Bhatt DL, Fox KA, Hacke W, et al; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006 Apr 20;354(16):1706-17. doi: 10.1056/NEJMoa060989.
31. James SK, Roe MT, Cannon CP, et al; PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011 Jun 17;342:d3527. doi: 10.1136/bmj.d3527.
32. Bonaca MP, Storey RF, Theroux P, et al. Efficacy and Safety of Ticagrelor Over Time in Patients With Prior MI in PEGASUS-TIMI 54. J Am Coll Cardiol. 2017 Sep 12;70(11):1368-1375. doi: 10.1016/j.jacc.2017.07.768.
33. Abtan J, Bhatt DL, Elbez Y, et al; REACH Registry Investigators. External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry. Int J Cardiol. 2023 Jan 1;370:51-57. doi: 10.1016/j.ijcard.2022.10.132.
34. Petrov VI. Basic principles and methodology of evidence-based medicine. Bulletin of VolgSMU. 2011; Release 2(38):3-8. (In Russ.).
35. High-quality clinical practice and the basics of evidence-based medicine. Methodological foundations of clinical research: a textbook for the system of higher and additional professional education of doctors in 2 volumes. Volume 1. Drapkina OM, Martsevich SYu, Bubnova MG, et al. Moscow: Russian Society for the Prevention of Non-Infectious Diseases, 2023. (In Russ.).
36. Verbitskaya EV, Belousov DYu, Kolbin AS. Evidence-based medicine: new in the search for evidence. Kachestvennaya klinicheskaya praktika = Good Clinical Practice. 2023;(3):15-28. (In Russ.). doi: 10.37489/2588-0519-2023-3-15-28.
Review
For citations:
Eliseeva E.V., Maneeva E.S., Tyrtyshnikova A.V., Li O.N., Gribova V.V., Okun D.B. Information service “Clinical Research Database” in the rational prescription of antiplatelet agents. Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2025;(4):19-37. (In Russ.) https://doi.org/10.37489/2588-0519-GCP-0002. EDN: DIPQVF
Views:
40
Email this article 